Header01-REBRAND_MENARINISILICONBIOSYSTEMS

 

Press Releases

12/10/2020

DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor


Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome

continue →

Topics: CELLSEARCH, metastatic breast cancer, HER2, San Antonio Breast Cancer Symposium, CTC phenotyping

08/4/2020

Two Studies Presented at AACR Meeting Deepen Understanding Of Cancer Mechanisms

Researchers Use Menarini’s Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment

continue →

Topics: CELLSEARCH, metastatic breast cancer, Multiple myeloma, HER2, AACR